Immunization with modified immunoglobulin (Ig) idiotypes (Ids) of B-cell lymphomas is an attractive approach of experimental tumor immunotherapy. We show here that B-lymphoma cells can be gene-modified by homologous recombination at the Ig heavy chain locus. Although it has been demonstrated previously that a protein vaccine containing a mouse/human chimeric Ig had no immunostimulatory effect, we show that a xenogeneic Fc segment attached to the Id by gene targeting in autologous murine tumor cells can serve as an immunogenic carrier and is capable of inducing tumor protection. A prerequisite for successful vaccination is the delivery of tumor cells that have been engineered to express the Id in the chimeric form rather than administration of the soluble chimeric protein. Also DNA vaccination with plasmids encoding chimeric Ids was reported to induce an anti-idiotypic response, suggesting that there might be related mechanisms such as enhanced antigen presentation. Immunization with engineered lymphoma cells is a very potent protocol: in the cell-based setting, minute levels of expression in the gene-targeted cells are sufficient to confer tumor immunity. Because the titers of anti-Id antibodies induced do not reflect the degree of tumor protection, the immune mechanisms responsible for tumor rejection cannot be ascribed exclusively to a humoral response. Cancer Gene Therapy (2000) 7, 501-506
D
espite recent advances in radiotherapy and chemotherapy, lymphomas of the B-cell lineage are still incurable. Therefore, immunotherapeutic approaches for the treatment of low-grade lymphomas have received much attention. A tumor-specific target antigen (Ag) expressed on the surface of malignant B cells is the immunoglobulin (Ig) idiotype (Id) that is the result of unique rearrangements of heavy and light chain variable (V) gene segments. Numerous studies with monoclonal antibodies (mAb) binding to Id determinants have been conducted in animal models and patients and have demonstrated the effectiveness of this approach (e.g., Refs. 1 and 2). Even long-lasting clinical remissions were observed. However, some patients relapsed due to ongoing somatic mutations in the rearranged IgV gene segments that led to escape variants no longer recognized by the therapeutic mAb. 3 It is generally accepted that this limitation may be surmounted by the induction of a polyclonal immune response against multiple epitopes using active immunization protocols. 4 Because the tumor Id is a weak Ag, successful immunization requires conjugation of the Id to carrier proteins or mixing with adjuvants, as demonstrated in a variety of animal models [5] [6] [7] [8] [9] [10] [11] and clinical trials. [12] [13] [14] [15] [16] Also, treatment with a lymphoma Id covalently coupled to granulocyte-macrophage colony-stimulating factor (GM-CSF) could elicit a tumor-protective response in mice. 17, 18 However, a xenogeneic Fc region attached to the tumorderived Ig was not a sufficient immunogenic carrier. 17 We have shown elsewhere that the effect of soluble modified Id proteins is significantly enhanced when autologous lymphoma cells engineered to express the modified Id are used as a vaccine instead of the protein preparation. 19, 20 Here we show that a xenogeneic Fc region can indeed induce tumor immunity when presented by autologous lymphoma cells whose Id is solely chimerized by substituting the murine IgH constant (C) exons with a human isotype by gene targeting. 21, 22 
MATERIALS AND METHODS

Vector construction
The construction of the vectors p3159, BCMGSNeo-V H A20-hu␥1-GMCSF, pSVgpt-hu␥1-A4, pSVgpt-hu␥1-A5, and pSVgpt-hu␥1-A6 has been described previously. p3159 (a gift from R. Levy, Stanford University, Stanford, Calif 17 ) and BCMGSNeo-V H A20-hu␥1-GMCSF 20 are expression vectors that contain the 38C13 and A20 V H gene, respectively, the human IgG1 C region fused to GM-CSF, and the gpt gene as a selection marker. The recombination vectors pSVgpt-hu␥1-A4, pSVgpt-hu␥1-A5, and pSVgpt-hu␥1-A6 contain a homology flank comprising 2.3, 3.0, and 5.8 kb, respectively, derived from the murine Ig intron, the human IgG1 C gene segments, and the gpt gene. 22 
Cell culture
38C13
23 is an IgM-expressing lymphoma derived from the C3H strain. A20 24 and MPC11 25 are lymphomas of BALB/c origin expressing IgG2a and IgG2b, respectively. The rat hybridoma 6C10 secretes a mAb with specificity against the A20 Id. 20 All cell lines were cultured in RPMI 1640 supplemented with 10% fetal calf serum, 2 mM glutamine, and 50 M 2-mercaptoethanol at 37°C. For transfection, 20 g of the recombination vector was linearized with EcoRI (which cuts within the homology region) or BamHI and mixed with 10 6 cells in 700 L of RPMI 1640. A single pulse of 220 V (38C13, MPC11) or 250 V (A20) and 960 F (38C13, A20) or 500 F (MPC11) was delivered in a gene pulser apparatus (Bio-Rad, München, Germany). After 10 minutes on ice, the cells were plated on 96-well dishes at a density of 10 4 cells/well. After 2 days, selection with xanthine, hypoxanthine, and escalating doses of mycophenolic acid was initiated. All stable clones were recloned by limiting dilution. For Ig purification, culture supernatants were passed over a protein A-Sepharose column (Bio-Rad) that was subsequently washed with phosphatebuffered saline and 0.1 M citric acid (pH 3.5).
Immunological methods
Transformants having undergone site-specific recombination were identified and characterized by enzyme-linked immunosorbent assay (ELISA) using a polyclonal goat anti-human IgGFc antibody (Ab) (Dianova, Hamburg, Germany), the 38C13-Id-specific mAb E4, 26 or the A20-Id-specific mAb 6C10 20 as capturing Abs. After incubation with culture supernatants or purified proteins, bound Ig was detected with peroxidase-labeled anti-human IgGFc (Dianova). The color reaction was started by adding o-phenylenediamine (Sigma, München, Germany) and H 2 O 2 .
To test sera for anti-Id responses, ELISAs were performed using purified 38C13, A20, or MPC11 Ig as the capturing Ab; peroxidase-labeled goat anti-mouse IgGFc (Dianova) that was absorbed against IgG2a (for A20) or IgG2b (for MPC11) was used as the detecting Ab. The reactivity of the sera with IgC domains was excluded by ELISA using irrelevant IgM, IgG2a, or IgG2b as the capturing Ab. To determine reactivities against unspecified tumor Ags, cellular ELISAs were performed. The 38C13, A20, or MPC11 cells were incubated with serially diluted mouse sera and then with peroxidase-labeled antimouse IgGFc absorbed against IgG2a or IgG2b. Preimmune sera served as controls. Serum titers were calculated as those reciprocal serum dilutions that gave a 2-fold extinction in the ELISA compared with naive mouse sera. The isotype distribution of immune responses was evaluated by fluorescence-activated cell sorter analyses. Binding activity against 38C13 and MPC11 cells in mouse sera was detected by fluorescein-coupled anti-IgG2a or -IgG1 mAb (Pharmacia, Uppsala, Sweden).
For Western blotting, 1 g of the purified protein was reduced, run on 10% sodium dodecyl sulfate-polyacrylamide gels, and blotted on to nitrocellulose filters that were developed with peroxidase-labeled anti-human IgGFc (Dianova).
Animal experiments
Groups of six C3H or BALB/c mice (Bommice, Ry, Denmark) were studied. Immunization was done intraperitoneally (i.p.) with 10 -50 g of protein or with 5 ϫ 10 6 recombinant tumor cells that were irradiated at a dose of 20 Gy. A boost was given after a 3-week interval, and the animals received a lethal i.p. challenge of wild-type (wt) tumor cells (200 38C13 cells, 10 5 A20 or MPC11 cells) after another 7 days. In serum transfer experiments, mice were injected i.p. with a lethal tumor dose that was mixed with 330 L per mouse of a 1/12 dilution of sera obtained from protected mice. For T-cell depletion, 0.2-0.5 g of the anti-CD8 mAb RmCD8 27 was given i.p. four times every 7-10 days starting 3 days before tumor inoculation. All experiments were done at least in duplicate. Statistical survival analysis was done using the log-rank test.
RESULTS AND DISCUSSION
Immunization with lymphoma cells with a gene-targeted chimeric Id
In previous experiments, 38C13 or A20 lymphoma cells were modified to express their Id in the context of GM-CSF. The cells were transfected with the expression vector p3159 or BCMGSNeo-V H A20-hu␥1-GMCSF, respectively, which contained the 38C13 or A20 V H gene segment and the human IgG1 C region, which was fused in frame to GM-CSF. 20 In the transfectants 1H7 (derived from 38C13) and 5C12 (A20-derived), the transferred IgH chains were correctly assembled with the endogenous Ig chains and secreted together with the parental Ig. The expression levels (250 and 25 ng/10 6 cells/24 hours for 1H7 and 5C12, respectively, as determined in culture supernatants and after purification by protein A chromatography) as well as the integrity of the fusion products were demonstrated by ELISA 20 using the anti-38C13-Id Ab E4 26 or the anti-A20-Id Ab 6C10, 20 anti-human IgGFc Ab, and anti-GM-CSF mAb. The correct size and the purity of purified proteins were verified by Western blotting; 20 the biological activity of the GM-CSF moiety could be demonstrated in a proliferation assay. 20 Syngeneic mice were immunized with the purified fusion proteins or with the irradiated Id/ GM-CSF-secreting tumor cells and subsequently challenged with a lethal wt tumor inoculum. As shown in Figure 1 , the tumor-protective effect of the cell-based vaccines was highly superior to that of the purified proteins, although the overall dose of fusion protein delivered by the modified cells was much lower than the dose that was administered in the protein-based setting. 20 This result prompted us to test whether Id xenogenization alone is sufficient for tumor immunization. To this end, lymphoma cells were modified using a system that is based on exchanging the IgH C exons with a human IgG1 region by homologous recombination; this strategy was exploited previously to generate chimeric Abs in hybridoma cell lines. 21, 22 38C13 and A20 cells were transfected with the vectors pSVgpt-hu␥1-A4 or pSVgpt-hu␥1-A5, 22 which comprise a selectable marker and the human IgG1 C region that was posed downstream of a homology flank derived from the murine Ig intron (Fig 2) . Integration into the IgH locus by homologous recombination occurs via the indicated breakpoint and gives rise to a murine V/human C chimeric sequence. Among the stable drug-resistant clones, gene-targeted transformants were detected by ELISA at a frequency of 1.3-3.1%. As in the majority of targeted hybridoma cells, 21 the parental murine isotype was coexpressed in addition to the chimerized heavy chain that was correctly assembled with the endogenous -chain of the lymphoma. Due to the low production rates of the parental lymphomas (17 and 30 ng/10 6 cells/24 hours for 38C13 and A20, respectively, as determined by ELISA) and the transcriptional down-regulation frequently accompanying homologous recombination, 21 the best human IgG1 producers identified after gene targeting (8BD7 as a 38C13-derivative and 4BE4 as an A20-derivative) produced at expression levels of only 5 and 10 ng/10 6 cells/24 hours, respectively. Chimeric Ig was predominantly secreted into the supernatant and could be purified quantitatively; only negligible additional amounts were recovered after lysis of the cells. The integrity of the proteins and the presence of the tumor Id were demonstrated by Western blotting and by ELISA using culture supernatants or purified Ig. For characterization, anti-human IgGFc Abs and the Id-specific Abs E4 and 6C10 were used, as outlined above.
C3H or BALB/c mice were immunized twice with irradiated 8BD7 or 4BE4 cells and subsequently challenged with lethal doses of 38C13 or A20 wt tumor cells, respectively. In both tumor models, almost all animals survived (Fig 3A) , whereas vaccination with unmodified, irradiated tumor cells was ineffective. Even A20 cells simultaneously injected together with irradiated 4BE4 cells were successfully rejected in five of six mice (data not shown). The immune response was specific, because an MPC11 challenge was not rejected in 4BE4-treated animals. Specific tumor protection was also observed in the Id/GM-CSF fusion approach (see above).
These results are in contrast to another study, 17 in which a purified chimeric 38C13 Id delivered systemically exerted no tumor-protective effect. Obviously, the xenogeneic Fc portion is indeed capable of stimulating immunity against the Id, but this seems to be dependent upon the use of engineered cells as a vaccine. In this setting, even minute expression rates of the modified cells are apparently sufficient to induce tumor immunity. Protein doses as high as 50 g were without effect, 17 whereas the total amount of accumulated protein produced by our irradiated cells in vivo did not exceed 10 ng. To directly compare the effects of cell-based and protein-based vaccination, a soluble xenogenized Id was prepared from the supernatant of a lymphoma cell line having undergone site-specific recombination. Because it was not possible to obtain enough protein from 8BD7 or 4BE4 cells for in vivo application, we selected for further study the MPC11 lymphoma whose Ig expression is 1000-fold higher than that of 38C13. Transfer of the vector pSVgpt-hu␥1-A6 into MPC11 cells resulted in targeted recombinants at a frequency of 3.2-5.4%. The chimeric Id was purified from the human IgG1 producer 2E12, characterized as outlined for 8BD7 and 4BE4, and used for immunization in comparison with the IgG1-expressing 2E12 cells. As shown in Figure 3B , 50% of the mice survived a lethal tumor challenge when immunized with 2E12 cells, whereas injection of the soluble protein provided no protection. This difference was statistically significant.
The tumor protection effect mediated by autologous lymphoma cells that were modified to express the Id in the context of GM-CSF was similar to that observed after sole chimerization of the Id. However, the tumorigenicity of viable xenogenized cells was not altered when compared with wt tumor cells, whereas the tumorigenicity of unirradiated Id/GM-CSF-expressing cells was abrogated (data not shown). This suggests that GM-CSF exerts an effect that is independent of that of the human IgG1 C region. 
Significance of anti-Id titers in vaccinated mice
When the humoral anti-Id response was determined in the sera of immune mice, an inverse hierarchy became evident compared with the in vivo protection effects. Surprisingly, the anti-Id titers measured after immunization with Id/GM-CSF fusion proteins markedly exceeded those that were obtained using the corresponding cellular vaccines ( Table 1) . As tumor immunity may be correlated with Abs directed against Ags other than the Id, we examined whether cellular immunization elicited higher levels of anti-whole cell Abs than protein immunization. This was, however, not the case (Table 1 ). An alternative explanation could be that the ratio of protective and nonprotective Ab subclasses varies depending upon the immunization scheme. However, a differential isotype distribution in mice injected with cells and protein was not observed when binding to lymphoma cells was tested by means of subclass-specific Abs.
To determine whether a humoral response contributed to tumor protection at all, passive serum transfer experiments were performed. Irrespective of treatment with 1H7 protein or 1H7 cells, the sera of vaccinated mice were able to confer tumor immunity, yielding 66 -83% longtime survivors in either setting (example in Fig 4) . This indicates that the humoral response does not merely reflect immunization, but contributes to tumor resistance. For the full penetrance of tumor resistance, however, cellular effectors may play a pivotal role, which may be activated more effectively by the cellular vaccine.
Immunization with cells that only expressed the chimeric Id also induced a very weak Ab response despite profound tumor protection. The reciprocal titers giving 2-fold background extinction ranged between three and six for 8BD7 and up to three for 2E12. In some protected mice, no Abs could be detected. In contrast to the sera obtained after treatment with the Id/GM-CSF fusion protein, the sera of 8BD7-or 2E12-vaccinated mice failed to convey tumor immunity to naive mice (shown for 8BD7 immune sera in Fig 4) . Thus, the tumor protection induced by chimeric Ids may be ascribed exclusively to nonhumoral immune mechanisms. The role of cellular effectors was directly proven by depletion experiments. The protective effect of 8BD7 cells was completely abrogated after Ab-mediated depletion of CD8 ϩ T cells (Fig 5) . Cellular effector systems mediating lymphoma rejection have also been postulated previously (e.g., in Refs. 5,6,10 and 16), but in those studies both anti-Id Abs and Idspecific T lymphocytes were found in vaccinated animals or patients. Whereas in other reports the correlation between tumor resistance and humoral response was stressed, 6, 8, 17 we observed tumor resistance in some cases despite the absence of Abs against lymphoma cells. The functional assessment of the induced Abs made here in addition to the comparison of cellular and protein vaccines revealed that anti-Id titers do not predict the tumor-protective effect, and that there may be a bias toward humoral or cellular effector mechanisms depending upon the form of the immunizing agent.
Concluding remarks
This study shows that a xenogeneic Fc region can serve as an immunogenic carrier for inducing anti-lymphoma immunity provided the chimeric Id is applied in the form of engineered autologous lymphoma cells. The superiority of a cell-based vaccine may be explained by an enhanced presentation of Id-related peptides by Agpresenting cells, such as macrophages, via major histocompatibility complex class II molecules, because these cells may ingest debris of the xenogenized tumor cells more readily than they uptake soluble chimeric Id protein. Moreover, the expression of the xenogeneic structure in the tumor cell itself should lead to targeting to the endogenous processing pathway and direct presentation via major histocompatibility complex class I. Recently, it was found that inclusion of a xenogeneic Fc portion in an Ig molecule induces an anti-Id response, when administered as a DNA vaccine, in contrast to the corresponding protein. 28 A prerequisite for the effectiveness of this approach, however, could be the expression of the plasmid in professional Ag-presenting cells. Thus, there may be, at least in part, different mechanisms underlying genetic immunization and the system described in this paper, because our engineered tumor cells are not professional Ag-presenting cells. In both settings, however, enhanced presentation will give rise to a more efficient activation of cytotoxic T lymphocytes specific for the xenogeneic sequences and, by virtue of a bystander effect, to T cells recognizing other tumor Ags.
